X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA VENUS REMEDIES SHASUN PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 123.9 -4.3 - View Chart
P/BV x 8.5 0.2 5,367.2% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 SHASUN PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
VENUS REMEDIES
Mar-18
SHASUN PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs94126 74.8%   
Low Rs4661 74.6%   
Sales per share (Unadj.) Rs214.2301.8 71.0%  
Earnings per share (Unadj.) Rs5.3-24.9 -21.5%  
Cash flow per share (Unadj.) Rs15.82.5 621.7%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %1.40-  
Book value per share (Unadj.) Rs53.3293.3 18.2%  
Shares outstanding (eoy) m56.6212.34 458.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.3 105.3%   
Avg P/E ratio x13.1-3.8 -348.4%  
P/CF ratio (eoy) x4.436.7 12.0%  
Price / Book Value ratio x1.30.3 411.0%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m3,9581,154 343.0%   
No. of employees `000NA0.9 0.0%   
Total wages/salary Rs m2,164393 550.4%   
Avg. sales/employee Rs ThNM4,026.1-  
Avg. wages/employee Rs ThNM425.0-  
Avg. net profit/employee Rs ThNM-331.8-  
INCOME DATA
Net Sales Rs m12,1273,724 325.6%  
Other income Rs m22923 1,019.3%   
Total revenues Rs m12,3563,747 329.8%   
Gross profit Rs m1,009395 255.6%  
Depreciation Rs m594338 175.5%   
Interest Rs m415354 117.2%   
Profit before tax Rs m230-275 -83.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-7332 -230.1%   
Profit after tax Rs m302-307 -98.4%  
Gross profit margin %8.310.6 78.5%  
Effective tax rate %-31.7-11.5 275.8%   
Net profit margin %2.5-8.2 -30.2%  
BALANCE SHEET DATA
Current assets Rs m6,8842,638 261.0%   
Current liabilities Rs m8,4562,305 366.9%   
Net working cap to sales %-13.08.9 -144.9%  
Current ratio x0.81.1 71.1%  
Inventory Days Days62135 45.5%  
Debtors Days Days10846 232.1%  
Net fixed assets Rs m4,9704,871 102.0%   
Share capital Rs m113123 91.8%   
"Free" reserves Rs m2,8753,496 82.2%   
Net worth Rs m3,0203,619 83.5%   
Long term debt Rs m1,8171,374 132.2%   
Total assets Rs m13,3477,509 177.8%  
Interest coverage x1.60.2 696.7%   
Debt to equity ratio x0.60.4 158.5%  
Sales to assets ratio x0.90.5 183.2%   
Return on assets %5.40.6 851.2%  
Return on equity %10.0-8.5 -118.0%  
Return on capital %13.31.6 842.1%  
Exports to sales %46.40-   
Imports to sales %14.213.9 102.7%   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728517 334.5%   
Fx inflow Rs m5,8430-   
Fx outflow Rs m2,173517 420.7%   
Net fx Rs m3,669-517 -710.5%   
CASH FLOW
From Operations Rs m398514 77.3%  
From Investments Rs m-1,635-123 1,328.2%  
From Financial Activity Rs m1,309-387 -338.1%  
Net Cashflow Rs m714 1,695.2%  

Share Holding

Indian Promoters % 39.2 32.9 119.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 0.2 2,000.0%  
FIIs % 17.6 0.6 3,034.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 66.4 59.6%  
Shareholders   20,750 20,121 103.1%  
Pledged promoter(s) holding % 12.3 36.4 33.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   SUVEN LIFE  MERCK LTD  SANOFI INDIA  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Realty & Auto Stocks Top Losers(09:30 am)

Asian shares eased in holiday-thinned trading on Monday and the safe haven yen gained as China canceled upcoming tariff talks with the United States.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS